OverviewChartNewsTraderScreen

HSBC Call 220 22UA 14.01.2026/  DE000HG81E45  /

Frankfurt Zert./HSBC
31/05/2024  21:35:29 Chg.-0.010 Bid21:57:39 Ask21:57:39 Underlying Strike price Expiration date Option type
0.200EUR -4.76% 0.200
Bid Size: 150,000		 0.220
Ask Size: 150,000		 BIONTECH SE SPON. AD... 220.00 - 14/01/2026 Call
GlobeNewswire 29/05 BioNTech and CEPI Expand Partnership to Strengthen Africa’s mRNA Vaccine Ecosystem
GlobeNewswire 21/05 BioNTech to Present Clinical Data Updates for Next-Generation Immunotherapy Candidates at the ASCO A...
GlobeNewswire 17/05 BioNTech SE Shareholders Approve All Agenda Items at the Annual General Meeting 2024
TeleTrader 06/05 BioNTech's Q1 revenue slumps 85% to €187.6M
GlobeNewswire 06/05 BioNTech Announces First Quarter 2024 Financial Results and Corporate Update
GlobeNewswire 22/04 BioNTech to Report First Quarter 2024 Financial Results and Corporate Update on May 6, 2024
GlobeNewswire 07/04 Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persis...
TeleTrader 20/03 BioNTech Q4 revenue plunges 65% to €1.48B
GlobeNewswire 20/03 BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
GlobeNewswire 20/03 BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer
GlobeNewswire 11/03 BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidat...
GlobeNewswire 07/03 BioNTech Announces Planned Retirement of Sean Marett
GlobeNewswire 06/03 BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update ...
GlobeNewswire 08/02 BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Exp...
GlobeNewswire 31/01 BioNTech and DualityBio Receive FDA Fast Track Designation for Next-Generation Antibody-Drug Conjuga...
GlobeNewswire 22/01 BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/...
TeleTrader 09/01 BioNTech sees $3.3B revenue for 2024, expanding into oncology
GlobeNewswire 09/01 BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire 21/12/2023 BioNTech and DualityBio Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Can...
GlobeNewswire 18/12/2023 BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
GlobeNewswire 12/12/2023 BioNTech to Inaugurate First African Site on December 18, 2023
TeleTrader 06/11/2023 BioNTech Q3 revenue plummets 74% to €895M
GlobeNewswire 06/11/2023 BioNTech Announces Third Quarter 2023 Financial Results and Corporate Update
GlobeNewswire 26/10/2023 Pfizer and BioNTech Announce Positive Topline Data for mRNA-based Combination Vaccine Program Agains...
GlobeNewswire 23/10/2023 BioNTech Presents Positive Phase 1/2 Data Update for CAR-T Cell Therapy Candidate BNT211 in Advance...